Search Within

Computational Oncology Service

  1. "Body Imaging Service"
Formats
  1. Journal Article (37)
  2. Meeting Abstract (16)
Groups
  1. Body Imaging Service (53)
  2. Epidemiology and Biostatistics (53)
  3. GSK Faculty (53)
  4. Radiology, Department of (53)
  5. Department of Medicine (51)
  6. Solid Tumor Oncology Division (50)

More Groups

People
  1. Nikolaus Schultz (29)
  2. David Solit (15)
  3. Matthew Hellmann (13)
  4. Francisco Sanchez Vega (12)
  5. Michael Berger (12)
  6. Kinh Gian Do (11)

More People

Years
  1. 2025 (3)
  2. 2024 (5)
  3. 2023 (4)
  4. 2022 (14)
  5. 2021 (3)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (14)
  2. Clinical Cancer Research (5)
  3. Cancer Discovery (4)
  4. Annals of Oncology (3)
  5. Cancer Research (2)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (16)
  2. American Association for Cancer Research (12)
  3. Oxford University Press (5)
  4. Nature Publishing Group (4)
  5. Elsevier Inc. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (53)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • An evaluation of the role of tumor load in cytoreductive nephrectomy
    Journal Article

    Silagy, A. W.; Duzgol, C.; Marcon, J.; DiNatale, R. G.; Mano, R.; Blum, K. A.; Reznik, E.; Voss, M. H.; Motzer, R. J.; Coleman, J. A.; more...
    CUAJ-Canadian Urological Association Journal (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial
    Journal Article

    Cercek, A.; Boerner, T.; Tan, B. R.; Chou, J. F.; Gönen, M.; Boucher, T. M.; Hauser, H. F.; Do, R. K. G.; Lowery, M. A.; Harding, J. J.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer
    Journal Article

    Vokes, N. I.; Liu, D.; Ricciuti, B.; Jimenez-Aguilar, E.; Rizvi, H.; Dietlein, F.; He, M. X.; Margolis, C. A.; Elmarakeby, H. A.; Girshman, J.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A rectal cancer organoid platform to study individual responses to chemoradiation
    Journal Article

    Ganesh, K.; Wu, C.; O’Rourke, K. P.; Szeglin, B. C.; Zheng, Y.; Sauvé, C. E. G.; Adileh, M.; Wasserman, I.; Marco, M. R.; Kim, A. S.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save